Last reviewed · How we verify
Cefazolin + Gentamicin
This combination uses a beta-lactam antibiotic (cefazolin) to inhibit bacterial cell wall synthesis and an aminoglycoside (gentamicin) to inhibit bacterial protein synthesis, providing synergistic broad-spectrum bactericidal activity.
This combination uses a beta-lactam antibiotic (cefazolin) to inhibit bacterial cell wall synthesis and an aminoglycoside (gentamicin) to inhibit bacterial protein synthesis, providing synergistic broad-spectrum bactericidal activity. Used for Surgical site infection prophylaxis, Serious gram-positive and gram-negative bacterial infections, Endocarditis prophylaxis in high-risk patients.
At a glance
| Generic name | Cefazolin + Gentamicin |
|---|---|
| Also known as | Ancef + Garamycin |
| Sponsor | Mercy Health Ohio |
| Drug class | Beta-lactam antibiotic + aminoglycoside antibiotic combination |
| Target | Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefazolin is a first-generation cephalosporin that binds penicillin-binding proteins and disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Gentamicin is an aminoglycoside that binds the 30S ribosomal subunit, inhibiting protein synthesis and causing bactericidal effects. Together, they provide enhanced coverage against gram-positive cocci and some gram-negative organisms, commonly used for surgical prophylaxis and serious infections.
Approved indications
- Surgical site infection prophylaxis
- Serious gram-positive and gram-negative bacterial infections
- Endocarditis prophylaxis in high-risk patients
Common side effects
- Nephrotoxicity
- Ototoxicity
- Hypersensitivity reactions
- Phlebitis at injection site
- Diarrhea
Key clinical trials
- Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic (NA)
- Local Antibiotics for Breast Implants (PHASE3)
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial (PHASE4)
- Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement (PHASE4)
- Modulation of Microbiota Metabolism in Cardiac Surgery Patients (NA)
- Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) (PHASE4)
- Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients (NA)
- Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |